REMEDI4ALL: an EU-funded research initiative to promote the repurposing of medicines in Europe

The platform has the potential to bring down times and costs of drug development by focusing on already approved, discontinued, shelved or investigational therapeutics.

The EU-funded platform - REMEDI4ALL – has been launched with the aim of gathering expertise in order to address the existing complexities of drug repurposing. The platform is funded under the Horizon Europe programme and it comprises 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement collaborating under the leadership of the European infrastructure for translational medicine (EATRIS).

REMEDi4ALL aims at:

  • build a state-of-the-art platform to provide expertise and services across the complete value chain (scientific, methodological, financial, legal, regulatory, intellectual property) for patient-centric medicine repurposing at every development stage and in any disease area.
  • assemble advanced in silico tools for Machine Learning (ML) and Artificial Intelligence (AI), open datasets and tools and expertise required to understand the mechanism of action of specific medicines.
  • create a global community of practice connected in a think-tank-like environment through impactful multidisciplinary activities and events.
  • train and educate the next generation of researchers, clinicians, patients, policymakers, regulators and funders in cutting-edge drug repurposing tools and processes.
  • favour dialogue and debate to advance policy and fair access to repurposed medicines across the EU.

REMEDi4ALL has selected four medicine repurposing projects in different stages of development to demonstrate the viability of the newly created platform. Each project covers a different therapeutic area with high unmet medical needs pancreatic cancer, COVID-19, rare diseases and ultra-rare diseases. These projects will first be onboarded to ensure a patient-centric approach before testing all elements of the platform to optimise its tools and services.

Full information on the project can be found here


Date: 28/11/2022 | Tag: | News: 1386 of 1414
All news

News

More news

Events

More events
newsletter

Subscribe to the VPH Institute Newsletter

ARCHIVE

Read all the newsletters of the VPH Institute

GO